Drugs / MITUMOMAB
MITUMOMAB
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00006352 | Sep 1999 → Oct 2002 | lung cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 3 | NCT00037713 | Sep 1998 → Oct 2002 | small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 3 | NCT00003279 | Mar 1998 → Jan 2000 | small cell lung carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MITUMOMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108442 ↗ |
| Known as | Bec2 | “This study reports the symptom and HRQOL results in which standard treatment was compared to standard therapy plus Bec2, an anti-idiotypic antibody that mimics GD3, a...” PMID 18676140 ↗ Oct 20084“Bec2 is an anti-idiotypic antibody that mimics GD3, a ganglioside that is expressed on the surface of tumor cells and is of neuroectodermal origin.” PMID 16192577 ↗ Oct 2005 |
| Known as | Mibumomab | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108442 ↗ |
| Modality | Monoclonal antibody | “adjuvant monoclonal antibody BEC2” NCT00003279 ↗ |
| Route | Other | “BEC2 and BCG intradermally on day 1 of weeks 0, 2, 4, 6, and 10” NCT00003279 ↗ |